HRP20010135A2 - Novel natural product derivatives - Google Patents

Novel natural product derivatives

Info

Publication number
HRP20010135A2
HRP20010135A2 HR20010135A HRP20010135A HRP20010135A2 HR P20010135 A2 HRP20010135 A2 HR P20010135A2 HR 20010135 A HR20010135 A HR 20010135A HR P20010135 A HRP20010135 A HR P20010135A HR P20010135 A2 HRP20010135 A2 HR P20010135A2
Authority
HR
Croatia
Prior art keywords
group
image
compounds according
formula
formulas
Prior art date
Application number
HR20010135A
Other languages
English (en)
Croatian (hr)
Inventor
Dieter Haebich
Siegfried Raddatz
Joachim Krueger
Rainer Endermann
Reinhold Gahlmann
Hein-Peter Kroll
Frank-Ulrich Geschke
Armin De Meijere
Vladimir N Belov
Victor Sokolov
Sergej Kozhushkov
Markus Kordes
Original Assignee
Bayer Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Ag filed Critical Bayer Ag
Publication of HRP20010135A2 publication Critical patent/HRP20010135A2/hr

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D233/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/04Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D233/28Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/44Nitrogen atoms not forming part of a nitro radical
    • C07D233/48Nitrogen atoms not forming part of a nitro radical with acyclic hydrocarbon or substituted acyclic hydrocarbon radicals, attached to said nitrogen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D235/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D235/14Radicals substituted by nitrogen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/20Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D239/22Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms directly attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Bakery Products And Manufacturing Methods Therefor (AREA)
HR20010135A 1998-08-27 2001-02-26 Novel natural product derivatives HRP20010135A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19838998A DE19838998A1 (de) 1998-08-27 1998-08-27 Neue Naturstoffderivate
PCT/EP1999/006124 WO2000012484A1 (de) 1998-08-27 1999-08-20 Tan-1057 derivate

Publications (1)

Publication Number Publication Date
HRP20010135A2 true HRP20010135A2 (en) 2002-02-28

Family

ID=7878913

Family Applications (1)

Application Number Title Priority Date Filing Date
HR20010135A HRP20010135A2 (en) 1998-08-27 2001-02-26 Novel natural product derivatives

Country Status (25)

Country Link
US (1) US6617332B1 (sk)
EP (1) EP1117652B1 (sk)
JP (1) JP4533535B2 (sk)
KR (1) KR20010099629A (sk)
CN (1) CN1324348A (sk)
AT (1) ATE267816T1 (sk)
AU (1) AU759618B2 (sk)
BG (1) BG105275A (sk)
BR (1) BR9913337A (sk)
CA (1) CA2342102C (sk)
DE (2) DE19838998A1 (sk)
EE (1) EE200100125A (sk)
ES (1) ES2219105T3 (sk)
HK (1) HK1041884A1 (sk)
HR (1) HRP20010135A2 (sk)
HU (1) HUP0103316A3 (sk)
ID (1) ID28365A (sk)
IL (1) IL141325A0 (sk)
NO (1) NO20010940L (sk)
NZ (1) NZ510153A (sk)
PL (1) PL346143A1 (sk)
SK (1) SK2622001A3 (sk)
TR (1) TR200100637T2 (sk)
WO (1) WO2000012484A1 (sk)
ZA (1) ZA200101038B (sk)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1113008A1 (en) * 1999-12-29 2001-07-04 Pfizer Products Inc. 4-oxo-2-ureido-1,4,5,6-tetrahydro-pyrimidine derivatives useful as antibacterial and antiprotozoal agents
US20040204404A1 (en) * 2002-09-30 2004-10-14 Robert Zelle Human N-type calcium channel blockers
EP2599781A1 (en) * 2007-12-20 2013-06-05 Dr. Reddy's Laboratories Ltd. Processes for the preparation of sitagliptin and pharmaceutically acceptable salts thereof
WO2011046007A1 (ja) 2009-10-15 2011-04-21 国立大学法人徳島大学 ジエチレントリアミン五酢酸誘導体の製造方法およびジエチレントリアミン五酢酸誘導体
MX339000B (es) 2009-10-16 2016-05-09 Melinta Therapeutics Inc Compuestos antimicrobianos y metodos para fabricar y utilizar los mismos.
JP6267863B2 (ja) 2009-10-16 2018-01-24 メリンタ セラピューティクス,インコーポレイテッド 抗微生物性化合物および抗微生物性化合物の製造方法および使用方法
CN108456211A (zh) * 2009-10-16 2018-08-28 梅琳塔治疗公司 抗微生物化合物和其制备和使用方法
KR20180051676A (ko) 2009-10-16 2018-05-16 멜린타 테라퓨틱스, 인크. 항미생물성 화합물 및 이의 제조 방법 및 사용 방법
PT2697229T (pt) 2011-04-15 2018-04-13 Melinta Therapeutics Inc Compostos antimicrobianos e seus métodos de fabrico e de utilização
RU2475479C1 (ru) * 2011-12-23 2013-02-20 Федеральное государственное бюджетное учреждение Министерства здравоохранения и социального развития Российской Федерации "Медицинский радиологический научный центр" (ФГБУ МРНЦ Минздравсоцразвития России) Вазоконстрикторное средство
CA2923179A1 (en) 2013-09-09 2015-03-12 Melinta Therapeutics, Inc. Antimicrobial compounds and methods of making and using the same
CA2923214A1 (en) 2013-09-09 2015-03-12 Melinta Therapeutics, Inc. Antimicrobial compounds and methods of making and using the same
EP3268370A4 (en) 2015-03-11 2018-08-22 Melinta Therapeutics, Inc. Antimicrobial compounds and methods of making and using the same

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2873340B2 (ja) * 1988-04-29 1999-03-24 武田薬品工業株式会社 抗生物質tan―1057,その製造法および用途
WO1999007685A1 (en) 1997-08-07 1999-02-18 Research Corporation Technologies, Inc. Antibiotic for methicillin resistant bacteria

Also Published As

Publication number Publication date
EP1117652A1 (de) 2001-07-25
BG105275A (en) 2001-11-30
DE19838998A1 (de) 2000-03-09
CA2342102C (en) 2008-10-28
US6617332B1 (en) 2003-09-09
HK1041884A1 (zh) 2002-07-26
ES2219105T3 (es) 2004-11-16
BR9913337A (pt) 2001-05-15
IL141325A0 (en) 2002-03-10
NO20010940L (no) 2001-04-23
CN1324348A (zh) 2001-11-28
TR200100637T2 (tr) 2001-10-22
NZ510153A (en) 2002-12-20
CA2342102A1 (en) 2000-03-09
KR20010099629A (ko) 2001-11-09
SK2622001A3 (en) 2001-11-06
HUP0103316A3 (en) 2002-06-28
ATE267816T1 (de) 2004-06-15
JP2002523496A (ja) 2002-07-30
EE200100125A (et) 2002-06-17
JP4533535B2 (ja) 2010-09-01
ID28365A (id) 2001-05-17
EP1117652B1 (de) 2004-05-26
NO20010940D0 (no) 2001-02-23
PL346143A1 (en) 2002-01-28
AU759618B2 (en) 2003-04-17
AU1009900A (en) 2000-03-21
DE59909607D1 (de) 2004-07-01
HUP0103316A2 (hu) 2002-04-29
WO2000012484A1 (de) 2000-03-09
ZA200101038B (en) 2002-02-07

Similar Documents

Publication Publication Date Title
US11236045B2 (en) Substituted sulfoximine compounds
TWI813610B (zh) 磺醯脲衍生物
EP3661921B1 (en) Selective inhibitors of nlrp3 inflammasome
CA2691987C (en) Antibacterial agents
AU2005304962A1 (en) Glycogen phosphorylase inhibitor compounds and pharmaceutical compositions thereof
HRP20010135A2 (en) Novel natural product derivatives
AU2013292580A1 (en) Beta amino acid derivatives as integrin antagonists
KR20130065728A (ko) Ahr 활성화제로서의 1,2-디히드로-4-히드록시-2-옥소-퀴놀린-3-카르복사닐리드
CA2696429A1 (en) Pyrrole compounds having sphingosine-1-phosphate receptor agonist or antagonist biological activity
CA3126467A1 (en) Novel substituted sulfonylurea derivatives
WO2020157069A1 (en) Amino heterocyclic compounds and uses thereof
CA2422135A1 (en) Urea derivatives and adhesion molecule inhibitors containing the same as effective ingredients
GB2264115A (en) 1h-2-methylimidazo(4,5-c)pyridinyl derivatives as paf antagonists
WO2008142623A2 (en) Tumor necrosis factor - alpha inhibitors
EP3983387B1 (en) Sulfonylurea derivatives and uses thereof
US20230096220A1 (en) Novel subtituted sulfonylurea and sulfoximineurea derivatives
CN113660983A (zh) 氨基甲酸酯衍生物及其用途
WO2020249664A1 (en) Sulfonylurea derivatives and uses thereof
MXPA01002058A (en) Tan-1057 derivatives
WO2021048809A9 (en) Novel substituted sulfoximine derivatives
CZ2001742A3 (cs) Nové deriváty přírodních látek
Muralikrishna et al. Synthesis of ureides containing indole moiety bearing-4-oxazetidinone
WO2020249669A1 (en) Sulfonamide derivatives and uses thereof
CA2787289A1 (en) Synthesis of substituted pyrazoline carboxamidine derivatives
NZ753087A (en) 2-amino-n-(arylsulfinyl)-acetamide compounds as inhibitors of bacterial aminoacyl-trna synthetase

Legal Events

Date Code Title Description
A1OB Publication of a patent application
ARAI Request for the grant of a patent on the basis of the submitted results of a substantive examination of a patent application
OBST Application withdrawn